Krystal Biotech Stock
Price
Target price
€208.60
€208.60
0.330%
0.7
0.330%
€207.83
12.12.25 / Tradegate
WKN: A2JH2F / Symbol: KRYS / Name: Krystal Biotech / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Krystal Biotech Stock
Krystal Biotech gained 0.330% compared to yesterday.
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
On the other hand, the target price of 207 € is below the current price of 208.6 € for Krystal Biotech, so the potential is actually -0.77%.
So far the community has only identified positive things for Krystal Biotech stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Krystal Biotech in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
| Champions Oncology Inc | -1.940% | 0.000% | -15.833% | -13.675% | 6.092% | -19.200% | -45.109% |
Comments
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $216.00 to $220.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
The comment is under review
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $182.00 to $255.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat